Inducing TRIB2-targeted protein degradation to reverse chemoresistance in acute myeloid leukaemia
Biochemical Journal · 08.04.2026 · 483 (4) · 511-525
DOI: 10.1042/bcj20253463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Journal, online erschienen am 30.03.2026. Verfasst von Evie Rigby und 13 weiteren Autor:innen. Beteiligte Einrichtung: Wolfson Wohl Translational Cancer Research Centre, School of Cancer Science, College of Medical, Veterinary and Life Sciences, University of Glasgow,…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Drug Resistance, Neoplasm, Proteolysis, Intracellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council UK, Biotechnology and Biological Sciences Research Council, UK, Medical Research Council confidence in concept.
Abstract (Originalsprache)
The myeloid oncogene TRIB2 is a key driver of acute myeloid leukaemia (AML) pathogenesis, promoting chemoresistance and blocking differentiation through ubiquitin-mediated degradation of the C/EBPα transcription factor. Despite its stable and sometimes elevated expression across AML subtypes, TRIB2 remains a clinically untargeted vulnerability. Here, we present a comprehensive investigation into TRIB2 degradation mechanisms using multimodal approaches, including CRISPR knockout, mutational protein stability, small molecule TRIB2 engagement, and evaluation of a novel targeted protein degrader (TRIB2-PROTAC). We identify afatinib, a multi-ERBB covalent inhibitor, as a rapid inducer of TRIB2 degradation, triggering AML cell death potentially via signalling pathways distinct from ERBB. Importantly, TRIB2 degradation synergised with cytarabine, the frontline AML chemotherapy, amplifying therapeutic efficacy. Mapping of TRIB2 ubiquitination sites revealed Lys-63 as critical for its own proteolytic turnover, and a Lys-to-Arg degradation-resistant mutant (KallR) conferred enhanced chemoresistance and increased leukaemic engraftment in vivo. CRISPR-mediated TRIB2 knockout validated an essential role in AML cell survival. Consistently, the novel TRIB2-PROTAC (compound 5K) achieved robust TRIB2 degradation and AML cell killing at low micromolar concentrations. These findings establish TRIB2 as a compelling therapeutic target in AML and demonstrate that leveraging the ubiquitin-proteasome system to degrade TRIB2 offers a promising strategy to overcome chemoresistance. The present work provides strong preclinical rationale for the development of TRIB2-targeting therapies in AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wolfson Wohl Translational Cancer Research Centre, School of Cancer Science, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, U.K.
- Department of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, U.K.
- School of Molecular Biosciences, College of Medical, Veterinary & Life Sciences, Davidson Building, Room, University of Glasgow, Glasgow, U.K.
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education of People's Republic of China, College of Pharmacy, Jinan University, Guangzhou,…
- Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
ORCID-Profile: Karen Keeshan
Förderung
- Medical Research Council UK
- Biotechnology and Biological Sciences Research Council, UK
- Medical Research Council confidence in concept
- Blood Cancer UK
- Medical Research Council
- Biotechnology and Biological Sciences Research Council
Zitieren
APA
Rigby, E., Fasanella Masci, F., Narayanan, A., Kania, E., Harris, J. A., Williams, J., Zhang, B., Liu, L., Richmond, L., Zhou, F., Ding, K., Carmody, R. J., Eyers, P. A., & Keeshan, K. (2026). Inducing TRIB2-targeted protein degradation to reverse chemoresistance in acute myeloid leukaemia. Biochemical Journal, 483(4), 511-525. https://doi.org/10.1042/bcj20253463
Vancouver
Rigby E, Fasanella Masci F, Narayanan A, Kania E, Harris JA, Williams J, et al. Inducing TRIB2-targeted protein degradation to reverse chemoresistance in acute myeloid leukaemia. Biochemical Journal. 2026;483(4):511-525. doi:10.1042/bcj20253463
BibTeX
@article{Rigby2026,
author = {Rigby, Evie and Fasanella Masci, Francesca and Narayanan, Akshara and Kania, Elzbieta and Harris, John A and Williams, Jamie and Zhang, Binghua and Liu, Lijun and Richmond, Laura and Zhou, Fengtao and Ding, Ke and Carmody, Ruaidhrí J and Eyers, Patrick A and Keeshan, Karen},
title = {Inducing TRIB2-targeted protein degradation to reverse chemoresistance in acute myeloid leukaemia},
journal = {Biochemical Journal},
year = {2026},
volume = {483},
number = {4},
pages = {511--525},
doi = {10.1042/bcj20253463}
}
EUVIMED